Successful treatment of osteonecrosis-induced fractured mandible with teriparatide therapy: A case report  by Yao, Mayumi et al.
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INTRODUCTION:  The  management  of  medication-related  osteonecrosis  of  the  jaw (MRONJ)  is controver-
sial.  To  date,  there  is  no established  treatment  for cases  of  advanced  stage  3 MRONJ  osteoporosis  in  elderly
patients.
PRESENTATION:  An  87-year-old  osteoporotic  woman  with  osteonecrosis-induced  left  mandible  fracture
related  to minodronate  therapy  was  referred  to  us  for treatment.  She  had  a  vertebral  compression  fracture
concurrently  and  had  started  subcutaneous  injection  of  teriparatide.  After  18  months  of  treatment  with
teriparatide the  pathological  mandible  fracture  was  healed  and  functional  recovery  of  the occlusion  wassteoporosis
lderly
obtained by  complete  dentures.
DISCUSSION:  Teriparatide  may have  a powerful  anabolic  effect  on  bone,  and  promote  bone  regeneration
against  pathologic  mandible  fracture  induced  by  MRONJ.
CONCLUSION:  Based  upon  these  ﬁndings,  teriparatide  might  be  beneﬁcial  for advanced  stage  3  MRONJ
osteoporosis  in elderly  patients.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Since bisphosphonate-related osteonecrosis of the jaw (BRONJ)
as ﬁrst reported [1], numerous cases have been identiﬁed [2]. The
merican Association of Oral and Maxillofacial surgery (AAOMS)
pdated their position paper on BRONJ in 2014, in which the term
RONJ was replaced with “medication-related osteonecrosis of the
aw” (MRONJ) [3]. Management of advanced MRONJ is both chal-
enging and controversial. An AAOMS position paper described that
hese patients beneﬁt from debridement, including resection, in
ombination with antibiotic therapy, which can offer long-term
alliation with resolution of acute infection and pain. Symptomatic
atients with stage 3 disease may  require resection and immedi-
te reconstruction. However, there is occasionally a case in which
andilectomy is not indicated because of age and primary illness.
Teriparatide (recombinant human PTH 1–34) is an osteoan-
bolic agent which induces bone formation [4], and is approved
or the treatment of postmenopausal osteoporosis, male osteo-
orosis and glucocorticoid-induced osteoporosis. Administration
f teriparatide for the treatment of MRONJ resistant to conventional
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treatment was  ﬁrst introduced by Harper and Fung [5]. Subse-
quently, several case reports have disclosed favorable therapeutic
outcomes from teriparatide in MRONJ [6–8]. We report here an 87-
year-old osteoporotic woman with an MRONJ-induced mandible
fracture that was successfully treated with teriparatide.
2. Case presentation
An 87-year-old woman  with a 2-year history of minodronic acid
hydrate (50 mg/4 w orally) for the treatment of osteoporosis was
referred to us in 2013 for treatment of a pathological mandibu-
lar fracture. She had undergone extraction of the left mandibular
ﬁrst molar 5 months earlier, and underwent oral irrigation for the
intraoral ﬁstula at another hospital. She had an incomplete occlu-
sion of the denture, and movement of the mandible bony fragment.
The infection of the soft tissue and mandible had extended to the
inferior border of the left mandible and emerged as an extraoral
ﬁstula (Fig. 1). Computed tomography revealed osteolysis extend-
ing to the inferior border resulting in a pathological fracture of
the left mandible (Fig. 2). A biopsy was  done and the histology
revealed chronic inﬂammation and sequestrum. She was  diagnosed
with stage 3 BRONJ. She had a vertebral compression fracture con-
currently and had started subcutaneous injection of teriparatide
(56.5 g/week) 1 month earlier. After discussion with the family
physician, teriparatide treatment was continued and conservative
treatment including amoxicillin hydrate administration (750 mg/d)
initiated. Six months after the initiation of teriparatide therapy,
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Extraoral view showing left submandibular extraoral ﬁstula.
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Fig. 3. Computed tomography after 18 months of teriparatide treatment.
Fig. 4. Extraoral view after 18 months of teriparatide treatment.Fig. 2. Computed tomography at the ﬁrst medical examination.
one sequestration of the left mandible had occurred, and the
atient was receiving intraoral sequestrectomy under local anes-
hesia. After 7 months of the treatment, her symptoms had resolved
nd the intraoral and extraoral ﬁstula had been converted to nor-
al  mucosa and skin respectively; therefore, administration of
he antibiotic was discontinued. After 18 months of treatment
ith teriparatide, computed tomography showed signiﬁcant bone
egeneration and recovery of the mandible bone continuity (Fig. 3).
hereafter, she obtained functional recovery of the occlusion by
omplete dentures (Fig. 4).
. Discussion
Teriparatide has been approved for osteoporosis management
9]. In addition to its effect on osteoporosis of increasing bone
ineral density and bone strength, it has the potential to allow
orrection of unstable vertebral fractures without surgical inter-
ention [10], and it promotes typical femoral fracture healing after
ong-term bisphosphonate administration [11]. Teriparatid is able
o reverse the anti-resorptive effect of bisphosphonates. It has been
hown to stimulate the activity and viability of osteoblasts from
he alveolar bone of chronic bisphosphonate users [12], while indi-
ectly increasing the metabolic activity and number of osteoclasts
y affecting osteoblast function [13]. Therefore, teriparatide ther-
py has the effect of improving bone formation and modulatingbone resorption at bisphosphonate therapy-induced pathological
fractured sites of the mandible. In this case, mobile bone sequester
was revealed 6 months after the teriparatide therapy was initiated.
These results suggested that teriparatide can effectively enhance
bone remodeling and separate the bone sequester for up to 6
months.
Successful cases of surgical resection of the mandible were
reported by Carson and Basile in 2009 [14]. Recently, resection of
MRONJ produced healing in patients taking oral bisphosphonate
more successfully than conservative management [15]. However,
aggressive resection of the jaw creates a difﬁcult problem of
delayed soft tissue coverage because osteoporosis patients are
usually elderly and their wound-healing ability impaired. Elderly
persons especially, i.e., those more than 80 years, have a charac-
teristic decrease in body functions and various kinds of coexistent
underlying disease. Therefore, when complications occur once,
there is the risk that a vital organ will fall into malfunction in a
chain reaction, and particularly careful operative adaptation and
perioperative care are required.
In conclusion, teriparatide therapy can provide an important
treatment option for advanced MRONJ stage 3 osteoporosis in
elderly patients.
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